US 12,411,127 B2
Measurement of hydrogen sulfide during breath testing
Mark Pimentel, Los Angeles, CA (US); Kapil Gupta, Los Angeles, CA (US); Ali Rezaie, West Hollywood, CA (US); and Nipaporn Pichetshote, Los Angeles, CA (US)
Assigned to CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Appl. No. 16/487,645
Filed by Cedars-Sinai Medical Center, Los Angeles, CA (US)
PCT Filed Feb. 23, 2018, PCT No. PCT/US2018/019490
§ 371(c)(1), (2) Date Aug. 21, 2019,
PCT Pub. No. WO2018/156937, PCT Pub. Date Aug. 30, 2018.
Claims priority of provisional application 62/589,484, filed on Nov. 21, 2017.
Claims priority of provisional application 62/502,350, filed on May 5, 2017.
Claims priority of provisional application 62/463,175, filed on Feb. 24, 2017.
Prior Publication US 2020/0064330 A1, Feb. 27, 2020
Int. Cl. B01L 3/00 (2006.01); A61K 31/437 (2006.01); B01F 33/302 (2022.01); B01F 33/3033 (2022.01); B01L 7/00 (2006.01); B01L 9/00 (2006.01); B65G 47/80 (2006.01); B82Y 20/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01); C12M 1/34 (2006.01); C12M 3/06 (2006.01); C12N 1/14 (2006.01); C12N 1/20 (2006.01); C12Q 1/02 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6844 (2018.01); C12Q 1/6848 (2018.01); C12Q 1/686 (2018.01); G01N 15/10 (2024.01); G01N 15/14 (2024.01); G01N 15/1433 (2024.01); G01N 21/29 (2006.01); G01N 21/65 (2006.01); G01N 33/497 (2006.01); G01N 33/543 (2006.01); G01N 33/557 (2006.01); G01N 33/574 (2006.01); G01N 33/58 (2006.01)
CPC G01N 33/497 (2013.01) [A61K 31/437 (2013.01); G01N 33/4975 (2024.05); G01N 2800/065 (2013.01); G01N 2800/52 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A method for selecting a therapy for a subject, and treating the subject, comprising:
obtaining a biological sample from a subject;
measuring the hydrogen sulfide (H2S) level in the biological sample during a test;
selecting a therapy for an H2S positive condition when the H2S level is higher than 1.2 ppm cut-off at any point during the test; and
administering the selected therapy to the subject to treat the H2S positive condition, wherein the H2S therapy comprises rifaximin,
wherein the H2S positive condition is selected from the group consisting of H2S positive diarrhea, H2S positive fatigue, H2S positive bowel urgency, H2S positive abdominal pain and combinations thereof,
wherein the biological sample is a breath sample.